论文部分内容阅读
目的:探讨舒利迭联合孟鲁司特治疗哮喘急性发作的临床疗效。方法:选取我院于2011年4月~至2013年6月收治哮喘急性发作患者86例,随机分为2组,对照组42例患者接受舒利迭治疗,观察组44例在对照组治疗基础上加用孟鲁司特治疗,对比2组患者临床治疗效果。结果:两种治疗方法均有显著疗效,观察组各项体征消失时间均显著短于对照组,肺功能改善情况优于对照组(P<0.05)。2组患者在治疗中均未出现严重不良反应。结论:在对哮喘急性发作展开治疗时,舒利迭联合孟鲁司特治疗可快速缓解患者临床症状,大幅提高患者生活质量,不良反应发生率低,临床疗效显著,值得在临床中推广。
Objective: To investigate the clinical efficacy of seretide plus montelukast in the treatment of acute asthma attacks. Methods: Eighty-six patients with acute asthma exacerbation were selected from April 2011 to June 2013 in our hospital and randomly divided into two groups. Forty-two patients in the control group were treated with seretide, while 44 in the observation group were treated in the control group On the increase with montelukast treatment, the clinical efficacy of two groups of patients compared. Results: Both treatments had significant curative effect. The disappearance time of all signs in the observation group was significantly shorter than that of the control group, and the improvement of pulmonary function was better than that of the control group (P <0.05). Two groups of patients in the treatment of no serious adverse reactions. Conclusion: In the treatment of acute exacerbation of asthma, the combination of seretide and montelukast can quickly relieve the patients’ clinical symptoms, greatly improve the quality of life of patients, the incidence of adverse reactions is low, and the clinical curative effect is significant. It is worth to be popularized clinically.